Articles tagged "Highly-sensitized"

2018 American Transplant Congress
CTLA4-Ig and Bortezomib Successfully Reverses Established DSA Responses in Allograft-Sensitized Recipients
D. Jain,¹ J. Young,¹ D. Yin,¹ R. Pelletier,² A. Chong.¹
¹Department or Surgery, University of Chicago, Chicago, IL; ²Department of Surgery, Ohio State University, Columbus, OH.
Background: Sensitized recipients have lower rates of transplantation and poorer outcomes. We and others have reported that the delayed administration of CTLA4-Ig can disrupt fully-established…
2018 American Transplant Congress
Tocilizumab Stabilizes Renal Function in Kidney Transplant Recipients with Chronic Active Antibody Mediated Rejection (CAAMR)
S. Patel, S. Mohan, H. Fernandez, I. Batal, L. Ratner, J. Crew.
Columbia University, New York.
INTRO: CAAMR after kidney transplantation (KTx) is associated with rates of allograft failure approaching 50% at 2 years from injury involving T cells, B cells,…
2018 American Transplant Congress
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
J. Choi,¹ O. Aubert,² S. Louie,¹ N. Ammerman,¹ A. Vo,¹ A. Peng,¹ E. Huang,¹ R. Najjar,¹ D. Puliyanda,¹ S. Sethi,¹ M. Haas,¹ K. Lim,¹ A. Loupy,² S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Paris Translational Center for Organ Transplantation, Paris, France.
Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…
2018 American Transplant Congress
A Follow-Up Report on the Use of IVIG+Rituximab to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly-Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
R. Najjar, E. Huang, A. Vo, J. Choi, K. Lim, S. Louie, A. Peng, S. Sethi, M. Toyoda, X. Zhang, S. Jordan.
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) with IVIG/rituximab is associated with a reduction in donor specific antibodies (DSA), improved transplant rates and outcomes in highly-sensitized (HS) patients. We…
2018 American Transplant Congress
Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients after Desenstization (DES): 3yrs Post Implementation
A. Vo, E. Huang, N. Ammerman, S. Williamson, C. Myers, A. Peng, R. Najjar, S. Sethi, K. Lim, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.
Introduction: The KAS aims to increase equity in organ allocation for broadly sensitized (HS) patients, especially (CPRA 99-100%). Coupling desensitization (DES) + KAS likely will…
2018 American Transplant Congress
Follow Up of Patients Treated with the IgG Endopeptidase (IdeS) for Desensitization and HLA Incompatible (HLAi) Kidney Transplantation
S. Jordan,¹ J. Choi,¹ E. Huang,¹ R. Najjar,¹ A. Peng,¹ X. Zhang,¹ S. Louie,¹ M. Haas,² S. Sethi,¹ I. Kim,¹ A. Vo.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction:Donor-specific antibodies (DSAs) create an immunologic barrier to transplantation. This prevents transplantation for a significant percentage of highly-HLA sensitized patients (HS). Current desensitization therapies are…
2018 American Transplant Congress
Molecular Monitoring for Kidney Allograft Injury Following HLA Incompatible Transplantation
A. Jackson,¹ B. Iglehart,¹ S. Bagnasco,³ N. Desai.²
¹Medicine, Johns Hopkins University, Baltimore, MD; ²Surgery, Johns Hopkins University, Baltimore, MD; ³Pathology, Johns Hopkins University, Baltimore, MD.
Elevated donor derived cell free DNA (ddcfDNA) has been shown to correlate with allograft rejection following heart, lung, and kidney transplantation. We investigated whether sequential…
2018 American Transplant Congress
Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG + Rituximab Desensitization (DES)
A. Vo,¹ O. Aubert,² H. Edmund,¹ A. Peng,¹ R. Najjar,¹ S. Supreet,¹ J. Choi,¹ K. Lim,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Paris Translational Research Center for Organ Transplantation, Necker Hospital, Paris, France.
Introduction: Highly-HLA sensitized patients (HS) with donor specific antibodies (DSA) at transplant are at risk for Type 1 ABMR. However, the incidence of Type 2…
2018 American Transplant Congress
The Clinical Significance of Pretransplant C1q Assay Status in Positive Crossmatch Kidney Transplantation
J. Lee,¹ D. Kim,¹ B. Park,² S. Song,³ J. Lee,⁴ Y. Jung,¹ J. Lee,¹ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Laboratory Medicine, Asan MEdical Center, Seoul, Korea; ³Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ⁴Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁵Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Patients with a pretransplant donor-specific antibodies (DSA) are at higher risk for antibody-mediated rejection (AMR). However, not all DSA have the same pathogenetic potential.…
2018 American Transplant Congress
Non Active Desensitization Protocol: Improving Access to Kidney Transplant for Hyperimmunized Patients
S. Le Bot,¹ F. Delbos,² C. Garandeau,¹ S. Malard Castagnet,² A. Cesbron,² M. Hourmant.¹
¹Nephrology and Transplantation, CHU Hôtel Dieu, Nantes, France; ²Laboratoire HLA, Etablissement Français du Sang, Nantes, France.
Hyperimmunized patients have a bad access to renal transplantation, despite national priority programs and active desensitization protocols. After having noticed that some HLA antibodies decreased…

« Previous Page
1
…
6
7
8
9
10
…
15
Next Page »